FAS and cancer: Indeed, the ability of IRE1 to dually regulate CD95-mediated cell death suggests that the preferential branch activated by this RNase in cancer cells could be one of the determinants of their response to endogenous immunosurveillance or even T-cell immunotherapy (Singh et al, 2020; Upadhyay et al, 2021).